PC
KERX

Pier Capital’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Pier Capital’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-140,437
Closed -$1.42M – 157
2013
Q3 		$1.42M Sell
140,437
-274,116
-66% -$2.44M 0.2% 97
2013
Q2 		$3.1M Buy
+414,553
New +$3.24M 0.47% 87

Other funds holding KERX

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Pier Capital's KERX Position: Q4 2013 in Review

Pier Capital sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2013, closing a stake of 140,437 shares — an estimated $1.42M sold.

Pier Capital first reported a position in KERX in Q2 2013 and held it in 2 quarters. The position peaked at $3.1M in Q2 2013. 124 funds tracked by Wall St. Rank hold KERX as of Q4 2013.

  • Pier Capital reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • Pier Capital sold 140,437 Keryx Biopharmaceuticals Inc shares in Q4 2013, an estimated $1.42M.
  • Pier Capital first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
  • Pier Capital's Keryx Biopharmaceuticals Inc position peaked at $3.1M in Q2 2013.
  • 124 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2013.

Based on Pier Capital's 13F filing for Q4 2013, filed 13 Feb 2014.